Table 2.
Immunohistochemical evaluation of protein expression of the selected target genes in various tumor categories.
| Gene | Chr | Status in RKO | Pilot study, n = 22 | % loss in MSS sporadic cancers, n = 43 (P value∗) | % loss in MSI sporadic cancers, n = 16 (P value) | % loss in sporadic adenoma, n = 12 (P value) | % loss in Lynch-colon cancers, n = 38 (P value) | % loss in FCCX, n = 19 (P value) | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IFI16 | 1q22 | Upregulated | Loss 43% not correlated with β-catenin localization | ND | ND | ND | ND | ND |
|
| |||||||||
| 2 | RGS4 | 1q23.3 | Upregulated | RGS4 nuclear localization in 56% of tumors correlated with nuclear β-catenin | 58% cytoplasmic (NS) | 50% cytoplasmic (NS) | ND | ND | ND |
|
| |||||||||
| 3 | MCTP1 | 5q15 | Upregulated | 50% membranous, 50% cytoplasmic, not correlated with β-catenin localization | ND | ND | ND | ND | ND |
|
| |||||||||
| 4 | DGKI | 7q32.3–q33 | Upregulated | Loss correlated with β-c a t e n i n localization | 55% (0.0001) | 69% (0.0001) | 30% (NS) | 63% (0.0001) | 50% (0.002) |
|
| |||||||||
| 5 | OBCAM/OPCML | 11q25 | Upregulated | Loss in 55% but not correlated with β-catenin localization | 60% (NS) | 50% (NS) | 70% (NS) | 68% (NS) | 15% (NS) |
|
| |||||||||
| 6 | GLIPR1 | 12q21.2 | Upregulated | Loss correlated with β-c a t e n i n localization | 33% (0.005) | 27% (0.005) | 27% (0.001) | 44% (0.001) | 40% (0.035) |
∗ P value is for loss of the expression versus β-catenin subcellular localization.
Highlighted in bold are GLIPR1 and DGKI findings which correlated with β-catenin status in a pattern similar to that observed in the microarray.
ND, not done; NS, not significant.